Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
Jingrong Ye,Yuan Dong,Yun Lan,Jing Chen,Ying Zhou,Jinjin Liu,Dan Yuan,Xinli Lu,Weigui Guo,Minna Zheng,Hong Yang,Xiao Song,Cong Liu,Quanhua Zhou,Chenli Zheng,Qi Guo,Xiaohui Yang,Lincai Zhang,Zhangwen Ge,Lifeng Liu,Fengting Yu,Yang Han,Huihuang Huang,Mingqiang Hao,Yuhua Ruan,Jianjun Wu,Jianjun Li,Qiang Chen,Zhen Ning,Xuemei Ling,Chang Zhou,Xuangu Liu,Jianyun Bai,Ya Gao,Xue Tong,Kangping Zhou,Fanghua Mei,Zhengrong Yang,Ao Wang,Wei Wei,Ruijuan Qiao,Xinhua Luo,Xiaojie Huang,Juan Wang,Xin Shen,Fengyu Hu,Linglin Zhang,Wei Tan,Jixiang Fan,Aixia Tu,Guolong Yu,Yong Fang,Shufang He,Xin Chen,Donglin Wu,Xinhui Zhang,Ruolei Xin,Xin He,Xianlong Ren,Conghui Xu,Yanming Sun,Yang Li,Guowu Liu,Xiyao Li,Junyi Duan,Tao Huang,Yiming Shao,Yi Feng,Qichao Pan,Bin Su,Tianjun Jiang,Hongxin Zhao,Tong Zhang,Faqing Chen,Bing Hu,Hui Wang,Jin Zhao,Kun Cai,Wei Sun,Baicheng Gao,Tielin Ning,Shu Liang,Yuqi Huo,Gengfeng Fu,Feng Li,Yi Lin,Hui Xing,Hongyan Lu
DOI: https://doi.org/10.1093/infdis/jiae303
2024-08-27
Abstract:Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH. Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.